Get startedLog in
    Picture of Cellivery Therapeutics logo

    268600 — Cellivery Therapeutics Income Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Cellivery Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue2,0747623,87223,15818,863
    Cost of Revenue
    Gross Profit-1,902-72370.6-269190
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses16,65818,37331,92193,41147,212
    Operating Profit-14,584-17,612-28,048-70,253-28,349
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-19,577-17,937-29,682-75,018-34,007
    Provision for Income Taxes
    Net Income After Taxes-19,650-17,248-28,069-75,159-34,036
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income-19,650-17,248-28,069-75,159-32,571
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Dilution Adjustment
    Diluted Net Income-19,650-17,248-28,069-75,159-32,571
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-632-535-834-2,900-694
    Dividends per Share